See Section 6.3 for the evaluation of measurable disease. 2.1.1.3 Subjects must have received one prior line of systemic chemotherapy as well as checkpoint therapy if checkpoint therapy is FDA approved for that specific tumor type (e.g., HNSCC and PDL1+ cervical cancer). Prior checkpoint therapy is not needed where checkpoint therapy has not been FDA approved for that specific tumor type (e.g. anal, vaginal, vulvar, penile, PDL1 negative cervical). Exceptions to the above include participant who are not eligible to receive the above therapies or who decline these standard treatment options after appropriate counseling has been provided. 2.1.1.4 Age >18 years. 2.1.1.5 ECOG performance status < 2. 2.1.1.6 Adequate hematologic function at screening, as follows: • Absolute neutrophil count (ANC) ≥1 x 109/L; • Hemoglobin ≥ 9 g/dL ; • Platelets ≥ 75,000/microliter. 2.1.1.7 Adequate renal and hepatic function at screening, as follows: • Serum creatinine ≤ 1.5 x upper limit of normal (ULN) OR Measured or calculated creatinine clearance ≥ 40 mL/min for participant with creatinine levels > 1.5 X institutional ULN (GFR can also be used in place of creatinine or CrCl ); • Bilirubin ≤ 1.5 x ULN OR in subjects with Gilbert’s syndrome, a total bilirubin ≤ 3.0 x ULN; • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN, unless liver metastases are present, then values must be ≤ 3 x ULN) . 2.1.1.8 The effects of the immunotherapies on the developing human fetus are unknown.